File Name,Date of Response,Responding FDA Center,Response to Petition,Cited Statutes or Regulations,Justification for Response,
FDA-2024-P-0105-0007_Response_Letter_from_FDA_CDER_to_Graviti_Pharmaceu.pdf,"April 5, 2024",Center for Drug Evaluation and Research (CDER),Denied (Glucotrol Tablets 5 mg and 10 mg were not withdrawn for safety or effectiveness reasons),Not Mentioned,"FDA reviewed its records and concluded that the drug products in question were not withdrawn from sale due to safety or effectiveness concerns; therefore, they will remain listed in the 'Discontinued Drug Product List' of the Orange Book",
FDA-2024-P-0109-0019_Interim_Response_Letter_from_FDA_CDER_to_Bausch_Lo.pdf,"June 24, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 C.F.R. § 10.30(e)(2),The FDA has not reached a decision on the petition due to the need to address other Agency priorities and resource constraints; the Agency will respond as soon as possible,
FDA-2024-P-0227-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"May 21, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 C.F.R. § 314.93; 21 C.F.R. § 314.94(a)(3)(iii),"FDA determined that the proposed change in strength does not pose questions of safety or effectiveness, aligns with the listed drug’s labeling recommendations, and does not require new investigations; if bioequivalence is demonstrated, the proposed product can be expected to have the same therapeutic effect",
FDA-2024-P-0279-0007_Final_Response_Letter_from_FDA_CDRH_to_Hyman__Phel.pdf,"May 31, 2024",Center for Devices and Radiological Health (CDRH),Denied,21 C.F.R. § 10.33; 21 C.F.R. § 10.35; 21 C.F.R. Part 16; Section 510(k) of the FD&C Act; 21 C.F.R. Part 807 Subpart E,The FDA found that the 510(k) clearance for Nautilus Nitrile Exam Gloves was based on invalid and duplicated biocompatibility data nearly identical to another unrelated submission; the justification offered by Nautilus (clerical error) was deemed implausible due to extensive evidence of duplication and manipulation; the agency concluded there was no genuine and substantial issue of fact and that allowing a stay or amendment would not serve public health or justice,
FDA-2024-P-0422-0011_Final_Response_Letter_from_FDA_CDER_to_Method_Phar.pdf,"August 27, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505B of the FD&C Act (PREA),"The proposed changes in strength and dosage form do not raise safety or effectiveness concerns, are consistent with labeled dosing recommendations, and would not require significant labeling changes; FDA also determined that although PREA applies, no pediatric studies are needed because the drug is already fully labeled for all pediatric age groups",
FDA-2024-P-0425-0008_Final_Response_Letter_from_FDA_CDER_to_RegCon_Solu.pdf,"August 27, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A) of the FD&C Act,"The proposed change from lyophilized powder to ready-to-use solution dosage form triggered Pediatric Research Equity Act (PREA) requirements; FDA determined that clinical trials are required for pediatric patients aged 12 to <17, and denied the waiver request for this age group; since such trials are needed, the petition is not eligible for approval under the ANDA pathway",
FDA-2024-P-0427-0007_Final_Response_Letter_from_FDA_CDER_to_DDReg_Pharm.pdf,"July 31, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i) and (iv); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A) of the FD&C Act,"The proposed changes in dosage form (to pessary), strength (400 mg vs. 90 mg), and indication/dosing regimen raise safety and effectiveness concerns and may require significant labeling changes; additionally, FDA determined that these are not permissible changes under the suitability petition pathway; therefore, the petition does not meet the statutory or regulatory requirements for approval",
FDA-2024-P-0435-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"May 20, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93(e)(1)(v); 21 CFR 10.33; 21 CFR 10.20,"FDA denied the petition because the reference listed drug (Nuplazid 17 mg) has been voluntarily withdrawn from sale and the Agency has not yet determined whether the withdrawal was for safety or effectiveness reasons; therefore, the petition cannot be approved under 21 CFR 314.93(e)(1)(v)",
FDA-2024-P-0521-0005_Interim_Response_Letter_from_FDA_CDER_to_Kasowitz_.pdf,"July 15, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),"The petition raises complex issues requiring extensive review and analysis; therefore, the FDA has not reached a decision and will respond once the review is complete",
FDA-2024-P-0522-0004_Interim_Response_Letter_from_FDA_CDER_to_Kasowitz_.pdf,"July 15, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),The FDA has not yet resolved the petition because it raises complex issues requiring extensive review and analysis by agency officials; a final response will be provided once a decision has been made,
FDA-2024-P-0526-0010_Response_Letter_from_FDA_CDER_to_Lupin_Inc_.pdf,"July 24, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A),"The proposed change from tablet to oral suspension dosage form triggered PREA requirements; FDA determined that clinical trials are required for pediatric patients due to the potential therapeutic benefit in treating DVT and PE; the request for a waiver of pediatric studies was denied, making the petition ineligible for approval under the ANDA pathway",
FDA-2024-P-0545-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"July 8, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); 21 CFR 314.93(e)(1)(iv); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A),"The proposed oral solution dosage form and 2 mg/mL strength differ from the reference listed drug’s labeling and pose questions of safety and effectiveness, requiring investigations and significant labeling changes; the proposed dosing regimen (12 mg/day) also deviates from the RLD’s (15 mg/day), increasing the risk of medication errors; therefore, the petition does not meet the statutory and regulatory criteria for approval",
FDA-2024-P-0666-0002_Acknowledgement_Letter_from_FDA_DMS_to_Royal_Diamo.pdf,"February 6, 2024","Dockets Management Staff (DMS), Office of Operations",Other – Acknowledgement of receipt; no decision issued on the petition’s substance,21 CFR 10.75,The letter acknowledges receipt and filing of the petition and clarifies that this is a procedural action only; it does not reflect any decision on the merits of the petition,
FDA-2024-P-0667-0013_Final_Approval_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"June 4, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.94(a)(3)(iii),"The proposed change in strength (3 g/100 mL) does not raise safety or effectiveness concerns, aligns with the listed drug’s labeling, and does not require new investigations; FDA concluded that the change would not jeopardize safe or effective use nor necessitate significant labeling changes",
FDA-2024-P-0761-0005_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"October 18, 2024",Center for Drug Evaluation and Research (CDER),Approved – Determination made that the drug was not withdrawn for safety or effectiveness reasons,Not Mentioned,"FDA determined that TAVIST (clemastine fumarate) tablet, 2.68 mg, was not withdrawn from sale for reasons of safety or effectiveness; therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-0805-0004_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"August 28, 2024",Center for Drug Evaluation and Research (CDER),Approved – Determination made that the drug was not withdrawn for safety or effectiveness reasons,Not Mentioned,"FDA determined that Fentanyl Citrate Injection (EQ 2.5 mg base/50 mL and EQ 5 mg base/100 mL) was not withdrawn from sale for reasons of safety or effectiveness; therefore, the products will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-0806-2474_Interim_Response_from_FDA_CFSAN_to_Center_for_Scie.pdf,"August 9, 2024",Center for Food Safety and Applied Nutrition (CFSAN),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),"The FDA was unable to reach a decision within 180 days of receiving the petition, which requests clarification on the applicability of menu labeling regulations to third-party platforms; review is ongoing",
FDA-2024-P-0827-0005_Final_Response_Letter_from_FDA_CDER_to_Aurobindo_P.pdf,"March 15, 2024",Center for Drug Evaluation and Research (CDER),Approved – Determination made that the drug was not withdrawn for safety or effectiveness reasons,Not Mentioned,"FDA determined that Duexis (ibuprofen and famotidine) tablet, 800 mg and 26.6 mg, was not withdrawn from sale for reasons of safety or effectiveness; therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-0889-0004_Final_Response_Letter_from_FDA_CVM_to_Aurora_Pharm.pdf,"May 2, 2024",Center for Veterinary Medicine (CVM),Approved,Section 512(n)(3) of the FD&C Act; 21 CFR 514.5,"The proposed change from chewable to oral solution dosage form for afoxolaner does not require new investigations to demonstrate safety or effectiveness; thus, it qualifies under a suitability petition and is approved accordingly",
FDA-2024-P-0973-0003_Interim_Response_Letter_from_FDA_CDER_to_Robin_Web.pdf,"August 15, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not resolved the petition due to prioritization of other agency matters; the Agency will respond once review is complete,
FDA-2024-P-1058-0003_Interim_Response_Letter_from_FDA_CDER_to_Aimed_All.pdf,"August 28, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2); 21 CFR 10.115,The petition raises complex issues requiring extensive review and analysis by Agency officials; FDA will respond once a final decision has been reached,
FDA-2024-P-1130-0004_Interim_Response_Letter_from_FDA_CDER_to_Valisure_.pdf,"August 28, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2); 21 U.S.C. § 372(a); 21 U.S.C. § 374(a); 21 U.S.C. § 375(b),"The petition raises complex issues regarding benzene contamination in benzoyl peroxide products, requiring extensive review and analysis by FDA officials; a final decision will be issued once review is complete",
FDA-2024-P-1131-0005_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"August 27, 2024",Center for Drug Evaluation and Research (CDER),Approved – Determination made that the drug was not withdrawn for safety or effectiveness reasons,Not Mentioned,"FDA reviewed its records and concluded that Diltiazem Hydrochloride in Dextrose 5% solution (125 mg/125 mL and 250 mg/250 mL, both 1 mg/mL) was not withdrawn from sale for safety or effectiveness reasons; therefore, the drug will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-1378-0003_Interim_Response_Letter_from_FDA_CDER_to_Organon_U.pdf,"August 14, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),"The petition raises complex issues concerning ANDA standards and guidance revisions for NEXPLANON (etonogestrel implant), requiring extensive review and analysis; FDA will respond once a decision has been reached",
FDA-2024-P-1379-0020_180_Day_Interim_Response_from_FDA_CFSAN_to_Physici.pdf,"September 16, 2024",Center for Food Safety and Applied Nutrition (CFSAN),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not been able to reach a decision on the petition within 180 days due to other agency priorities and limited resource availability; a decision will be issued upon completion of the review,
FDA-2024-P-1380-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,"August 29, 2024",Center for Veterinary Medicine (CVM),Denied,5 U.S.C. § 552(a)(2)(D); 29 U.S.C. § 794d(a) (Section 508 of the Rehabilitation Act of 1973),"CVM stated that it complies with FOIA posting requirements when the conditions under 5 U.S.C. § 552(a)(2)(D) are met, and records will be posted once they are converted into a Section 508-compliant format to ensure accessibility for individuals with disabilities; thus, the petition was denied",
FDA-2024-P-1403-0008_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"September 30, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A); 21 CFR 10.33; 21 CFR 10.20,"FDA denied the petition because the proposed change in dosage form (from capsules to orally disintegrating tablets) triggers pediatric study requirements under PREA; the proposed products may offer meaningful therapeutic benefits in pediatric patients, especially those under 50 kg, but the current labeling does not support pediatric use for this group; since the request for a waiver was denied and clinical trials are required, the petition cannot proceed under the ANDA pathway",
FDA-2024-P-1440-0003_Interim_Response_Letter_from_FDA_CDER_to_pH_D_Femi.pdf,"September 17, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not yet resolved the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,
FDA-2024-P-1441-0013_Final_Response_Letter_from_FDA_CDER_to_Epic_Pharma.pdf,"February 13, 2025",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed changes in strength and dosage form (to 200 mg/20 mL and 350 mg/35 mL, both 10 mg/mL) do not pose questions of safety or effectiveness; the uses and route of administration are the same as the listed drug, and the proposed changes align with labeling recommendations; bioequivalence must be demonstrated, but no new investigations are required",
FDA-2024-P-1483-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"August 1, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed change in strength (total drug content) from the listed drug product does not raise questions of safety or effectiveness; the uses, dose, dosage form, and route of administration remain the same; the proposed change aligns with labeling recommendations, and no new investigations are needed if bioequivalence is demonstrated",
FDA-2024-P-1570-0004_180_Day_Response_Letter_from_FDA_CFSAN_to_Bongards.pdf,"September 19, 2024",Center for Food Safety and Applied Nutrition (CFSAN),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not reached a decision on the petition due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,
FDA-2024-P-1715-0004_Interim_Response_Letter_from_FDA_CDER_to_AbbVie_In.pdf,"September 19, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not resolved the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,
FDA-2024-P-1716-0005_Response_Letter_from_FDA_CVM_to_Aurora_Pharmaceuti.pdf,"June 27, 2024",Center for Veterinary Medicine (CVM),Denied,Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act; 21 CFR Part 10; 21 CFR 10.33(e); 21 CFR 10.25(a),"The petition proposed a meloxicam oral solution with a 10-fold increase in strength (5 mg/mL vs. 0.5 mg/mL in the RLNAD), raising concerns about potential user error and safety due to the similarity in appearance of the two concentrations and incorrect dosage delivery; these concerns would require additional investigations to demonstrate safety, making the petition ineligible under the suitability provision",
FDA-2024-P-1717-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,"October 3, 2024",Center for Veterinary Medicine (CVM),Denied,5 U.S.C. § 552(a)(2)(D); 29 U.S.C. § 794d(a) (Section 508 of the Rehabilitation Act of 1973),"CVM explained that it complies with FOIA posting requirements when the threshold for frequent requests is met and the records have been released; however, records must be converted to Section 508-compliant formats to ensure accessibility for individuals with disabilities before posting; based on this policy, the petition was denied",
FDA-2024-P-1788-0008_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"July 25, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed strength change (from 4 mg to 2 mg) does not raise safety or effectiveness concerns, aligns with dosing recommendations in the labeling of the listed drug, and would not require significant labeling changes or additional investigations if bioequivalence is demonstrated; therefore, the petition is approved",
FDA-2024-P-1810-0008_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"August 23, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed change in strength (from 50 mg/vial to 100 mg/vial) does not pose questions of safety or effectiveness; the uses, dose, dosage form, and route of administration are the same as the listed drug; the proposed strength is consistent with dosing recommendations; if bioequivalence is shown, the new strength is expected to have the same therapeutic effect without requiring significant labeling changes or new investigations",
FDA-2024-P-1870-0007_Final_Response_Letter_from_FDA_CDER_to_Newcastle_B.pdf,"October 15, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505B of the FD&C Act (PREA); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed change in strength and dosage form (to orally disintegrating tablets of 5 mg, 10 mg, 15 mg, and 20 mg) does not raise questions of safety or effectiveness, aligns with labeling of the reference listed drug, and does not require new investigations; the product is also appropriately labeled for pediatric patients 7 years and older, and pediatric studies for those under 7 are impracticable, thus a waiver is granted",
FDA-2024-P-1871-0007_Interim_Response_Letter_from_FDA_CDER_to_Advanced_.pdf,"October 7, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not resolved the issues raised in the petition due to the need to address other Agency priorities; the Agency will respond as soon as possible,
FDA-2024-P-1913-0006_Final_Response_Letter_from_FDA_CDER_to_Fast_Track_.pdf,"August 20, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv),"FDA determined that the proposed change in strength (to 50 mg/5 mL, 10 mg/mL) does not raise questions of safety or effectiveness; the uses, dose, dosage form, and route of administration remain the same as the listed drug; the proposed strength is consistent with labeling recommendations and, if bioequivalence is demonstrated, no significant labeling changes or new investigations are required",
FDA-2024-P-1916-1820_Final_Response_Letter_from_FDA_CVM_to_Association_.pdf,"October 18, 2024",Center for Veterinary Medicine (CVM),"Denied (in part as moot, in part as outside the scope of the citizen petition process)",21 CFR 10.30(e)(2)(iii); 21 CFR 10.30(b)(3); 21 CFR 10.3(a); 21 CFR 10.30(j),"The petition was dismissed in part as moot because FDA had already published a public summary addressing the requested information regarding adverse events linked to Purina pet food; the remaining request was denied as it fell outside the scope of permissible administrative actions under the citizen petition process, since requests for updates to investigations and public dissemination of non-record-based information are not administrative actions",
FDA-2024-P-1960-0003_Final_Response_Letter_from_FDA_ORA_to_Kohl_Harring.pdf,"October 11, 2024",Office of Regulatory Affairs (ORA),Denied,5 U.S.C. § 552(a)(2)(D); 21 CFR 10.30(e)(3); 21 CFR 10.30(b)(3),"FDA denied the petition because, although at least three FOIA requests had been received for the Lystn, LLC records, the agency had not yet released those records publicly — a prerequisite for mandatory posting under 5 U.S.C. § 552(a)(2)(D); once the records are reviewed and released under FOIA, they will be posted accordingly",
FDA-2024-P-1988-0004_Interim_Response_Letter_from_FDA_CDER_to_HealthyWo.pdf,"October 16, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),The petition raises complex issues requiring extensive review and analysis by FDA officials; the agency will respond once a decision is reached,
FDA-2024-P-2084-0006_Interim_Response_Letter_from_FDA_HFP_to_PETA_Found.pdf,"October 22, 2024",Human Foods Program (HFP),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not been able to reach a decision on the petition within the 180-day timeframe due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,
FDA-2024-P-2085-0007_Final_Response_Letter_from_FDA_CDER_to_Hospira_Inc.pdf,"August 12, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93(e)(1)(vi); 21 CFR 314.94(a)(9)(iii); 21 CFR 10.33; 21 CFR 10.20; 21 CFR 314.93(a)-(b),"FDA denied the petition because a pharmaceutically equivalent drug product (Vancomycin Hydrochloride for Injection, 1.25 g base/vial) has already been approved under NDA 209481; under 21 CFR 314.93(e)(1)(vi), a suitability petition cannot be approved if a drug product is already approved in an NDA for the change described; a change in excipients in a parenteral product is not a permissible change under section 505(j)(2)(C) of the FD&C Act",
FDA-2024-P-2148-0004_Final_Response_Letter_from_FDA_CDER_to_Neşe_Deveno.pdf,"May 30, 2024",Center for Drug Evaluation and Research (CDER),Partially approved,21 CFR 14.25(a); 21 CFR 14.29; 21 CFR 14.29(b)(2),"FDA granted the request to convene an advisory committee meeting and extended the open public hearing (OPH) from one hour to one hour and 45 minutes due to high interest. However, the request to prioritize input from certain stakeholders was denied, as FDA does not give preferential scheduling to any group. The committee will discuss the benefit-risk profile of MDMA capsules submitted by Lykos Therapeutics for treating PTSD",
FDA-2024-P-2150-0009_Response_Letter_from_FDA_CDER_to_Parenteral_Techno.pdf,"October 9, 2024",Center for Drug Evaluation and Research (CDER),Denied,"21 U.S.C. § 352; 21 U.S.C. § 352(a); 21 U.S.C. § 352(f); 21 CFR § 201.5; 21 CFR §§ 201.66(a), 201.66(c)(6); 21 CFR 10.30(k); Section 505G of the FD&C Act","The petition was denied because requests to initiate enforcement actions are not appropriate subjects for citizen petitions under 21 CFR 10.30(k). Although the FDA acknowledged the concerns raised about OTC acetaminophen labeling for infants, it noted that such decisions are discretionary and outside the scope of the citizen petition process. However, the FDA stated it intends to propose a safety-related order to update pediatric acetaminophen labeling under the OTC monograph process pursuant to Section 505G of the FD&C Act",
FDA-2024-P-2151-0126_Interim_Response_Letter_from_FDA_HFP_to_UnidosUS.pdf,"November 4, 2024",Human Foods Program (HFP),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not been able to reach a decision on the petition due to other agency priorities and limited availability of resources; the agency will notify the petitioner once the review is complete,
FDA-2024-P-2215-0003_Interim_Response_Letter_from_FDA_CDRH_to_Metaltron.pdf,"October 28, 2024",Center for Devices and Radiological Health (CDRH),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),FDA has not reached a decision because the petition raises issues requiring further review and analysis; the agency will respond once a decision has been made,
FDA-2024-P-2220-0005_Final_Response_Letter_from_FDA_CDER_to_Encube_Ethi.pdf,"August 20, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not Mentioned,"FDA determined that Pennsaid (diclofenac sodium) topical solution, 2%, was not withdrawn from sale for reasons of safety or effectiveness and therefore will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-2242-0002_Acknowledgment_Letter_from_FDA_DMS_to_David_Behar_.pdf,"May 7, 2024",Dockets Management Staff (DMS),Acknowledged (no decision on substantive merits),21 CFR 10.30,"The petition dated April 28, 2024, was received and processed under 21 CFR 10.30; however, acceptance for filing is procedural and does not reflect a decision on the petition's substantive merits",
FDA-2024-P-2272-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"June 24, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not Mentioned,"FDA determined that Invega (paliperidone) extended-release tablet, 1.5 mg, was not withdrawn from sale for reasons of safety or effectiveness, and therefore it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-2314-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"October 2, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not Mentioned,"FDA determined that Augmentin XR (amoxicillin; clavulanate potassium) Extended-release Tablets, 1 gm; EQ 62.5 mg base, was not withdrawn from sale for reasons of safety or effectiveness and therefore will remain listed in the 'Discontinued Drug Product List' section of the Orange Book",
FDA-2024-P-2326-0009_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"August 16, 2024",CDER (Center for Drug Evaluation and Research),Denied,"21 U.S.C. 355(b)(2), 21 CFR 314.3(b), 21 CFR § 314.110(a), 21 CFR parts 210 and 211, section 505(d), section 501(a)(2)(B), ICH Q7 guidance","The FDA denied the petition on the grounds that rescission of tentative approval for Yutrepia was not warranted, as Liquidia's current API supplier, Yonsung, is the actual manufacturer and LGM is not physically handling the drug. LGM's obligations under a Consent Decree were deemed irrelevant to the current manufacturing supply chain, and thus did not justify issuing a complete response letter or withholding approval.",
FDA-2024-P-2379-0009_Interim_Response_Letter_from_FDA_CDER_to_The_Human.pdf,"November 1, 2024",Center for Drug Evaluation and Research (CDER),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2),"FDA has not reached a decision due to the need to address other agency priorities. The response acknowledges the petition's request to clarify requirements for drug approval in accordance with the FDCA and FDORA, including the acceptance of data from new alternative methods (NAMs), and states that a final response will be issued as soon as possible",
FDA-2024-P-2461-0003_Interim_Response_from_FDA_CTP_to_Ho_Chunk__Inc__on.pdf,"November 12, 2024",Center for Tobacco Products (CTP),Interim response – FDA has not yet made a final decision on the petition,21 CFR 10.30(e)(2)(iv),"FDA has not reached a decision within 180 days due to the complexity of the issues raised, which require additional review and consideration. The petition requests an exemption for tribally-owned cigarette manufacturers from proposed tobacco manufacturing regulations, and FDA is continuing its review in the context of other program priorities.",
FDA-2024-P-2482-0002_Acknowledgment_Letter_from_FDA_DMS_to_Age_Reversal.pdf,"May 22, 2024","Dockets Management Staff (DMS), FDA/Office of Operations (OO)",Acknowledged (no decision on substantive merits),21 CFR 10.30,"The petition dated May 7, 2024, was received and assigned a docket number. Acceptance for filing is procedural and does not indicate any decision on the petition's substantive merits.",
FDA-2024-P-2513-0004_Final_Response_Letter_from_FDA_CDER_to_Innogenix__.pdf,"September 5, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not explicitly cited; determination was based on internal FDA review and Orange Book policy,"FDA reviewed its records and determined that Flagyl (metronidazole) Tablets, 250 mg and 500 mg, were not withdrawn for reasons of safety or effectiveness. Therefore, they will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",
FDA-2024-P-2514-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"November 13, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not explicitly cited,"FDA determined that Nuplazid (pimavanserin tartrate) tablet, EQ 17 mg base, was not withdrawn from sale for safety or effectiveness reasons. Therefore, it will remain listed in the 'Discontinued Drug Product List' section of the Orange Book.",
FDA-2024-P-2515-0005_Final_Response_Letter_from_FDA_CDER_to_Encube_Ethi.pdf,"November 20, 2024 ","Center for Drug Evaluation and Research (CDER), Office of Regulatory Policy ",FDA determined that FORTESTA (testosterone) gel 10 mg/0.5 g actuation was not withdrawn for reasons of safety or effectiveness and will remain in the Orange Book’s Discontinued Drug Product List ,Not Mentioned,"FDA reviewed its records and found no evidence of safety or effectiveness concerns related to FORTESTA’s withdrawal; therefore, the drug’s discontinued status is maintained and a Federal Register notice will announce this determination ",
FDA-2024-P-2625-0004_Response_Letter_from_FDA_ORA_to_J_R_Imports_LLC_Re.pdf,"October 18, 2024 ",Office of Regulatory Affairs (ORA) ,Petition for reconsideration and stay of Import Alert #99‑41 is denied ,"21 C.F.R. §§ 10.25, 10.30, 10.33, 10.35, 10.3; 21 C.F.R. §§ 1.505, 1.506, 1.507, 1.514; 21 U.S.C. §§ 381, 384a; Section 301 FSMA; Import Alert #99‑41 ","JR Imports repeatedly failed to develop and follow Foreign Supplier Verification Program (FSVP) plans despite multiple inspections, warning letters, and Form 483 observations; petition offered no new or inadequately considered information, did not establish irreparable injury, and public‑health interests in safe imported food outweigh firm’s request; therefore FDA denies reconsideration and stay and maintains listing on Import Alert #99‑41 ",
FDA-2024-P-2730-0003_Response_Letter_from_FDA_CBER_to_Kenneth_D__Eichen.pdf,"July 12, 2024",Center for Biologics Evaluation and Research (CBER),Denied,42 U.S.C. § 262(a) (Public Health Service Act § 351(a)); 21 CFR 600.3(s); Section 505(d) of the FD&C Act; Section 115(a) of the FDAMA; 21 CFR 314.126; Section 506(c)(1)(A) and 506(c)(2)(D) of the FD&C Act; 21 CFR 601.41,"FDA concluded that Sarepta provided substantial evidence of effectiveness to support traditional approval of ELEVIDYS for ambulatory patients aged 4 and older and accelerated approval for non-ambulatory patients aged 4 and older with DMD. The EMBARK study, though not meeting its primary endpoint, demonstrated clinically meaningful benefits. Micro-dystrophin levels supported predicted clinical benefit in non-ambulatory individuals. FDA found the benefit-risk profile favorable given the serious nature of the disease and the unmet medical need. Petitioner's assertions did not justify denying approval or reevaluating ELEVIDYS’s favorable risk-benefit determination.",
FDA-2024-P-2752-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"November 6, 2024",Center for Drug Evaluation and Research (CDER),Approved,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv)","FDA determined that the proposed change in strength (total drug content) does not raise questions of safety or effectiveness. The uses, dose, dosage form, and route of administration are the same as those of the listed drug, and the change is consistent with the listed drug's labeling. If shown to be bioequivalent, the proposed drug products are expected to have the same therapeutic effect as the reference listed drug. No new investigations are needed to demonstrate safety or effectiveness.",
FDA-2024-P-2753-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"October 17, 2024",Center for Drug Evaluation and Research (CDER),Approved,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii); Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv)","FDA found that the proposed change in strength does not raise safety or effectiveness concerns. The proposed drug products share the same use, dose, dosage form, and route of administration as the listed drug. The change is consistent with the RLD’s labeling, and if the products are shown to be bioequivalent, they are expected to have the same therapeutic effect. Therefore, additional investigations are not required to establish safety or effectiveness.",
FDA-2024-P-2757-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"December 10, 2024",Center for Drug Evaluation and Research (CDER),Denied,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(iv); 21 CFR 10.20; 21 CFR 10.33","FDA determined that the proposed change in strength introduces new risks, including medication errors, inappropriate use, expired drug use, and potential overdose. Addressing these issues would require significant labeling changes to multiple sections including Dosage and Administration, Overdosage, and Warnings and Precautions. Because these changes raise safety and effectiveness concerns not present with the reference listed drug, the petition is denied.",
FDA-2024-P-2757-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"December 10, 2024",Center for Drug Evaluation and Research (CDER),Denied,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93",Request to permit the submission of an ANDA for Oxytocin Injection pharmacy bulk packages with different strengths than the reference listed drug,"FDA concluded that the proposed strengths introduce new safety and effectiveness concerns, including potential for medication errors such as product preparation errors, inappropriate use, expired drug usage, and wrong dose errors—necessitating significant changes to labeling (Dosage and Administration, Overdosage, Warnings and Precautions)"
FDA-2024-P-2778-0013_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"December 23, 2024",Center for Drug Evaluation and Research (CDER),Denied,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 505B of the Act (Pediatric Research Equity Act)","The FDA denied the petition because the proposed change in dosage form triggers the Pediatric Research Equity Act (PREA), which requires pediatric clinical trials; a full waiver of these requirements was also denied, making the product ineligible for approval via an ANDA.",
FDA-2024-P-2779-0012_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"January 21, 2025",CDER (Center for Drug Evaluation and Research),Denied,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93(e)(1)(i), (iv); 505(j)(2)(A)","The proposed change in strength to 12.5 mg raises questions of safety and effectiveness not addressed by the reference listed drug (RLD) labeling. Investigations are required to show safety and efficacy. The proposed strength also introduces potential for medication errors, requiring significant labeling changes to address safety concerns.",
FDA-2024-P-2843-0002_Acknowledgment_Letter_from_FDA_DMS_to_Zach_Richard.pdf,2024-06-13,DMS (Division of Dockets Management Services),Acknowledged,Not Mentioned,Not Mentioned,
FDA-2024-P-2846-0004_Final_Response_Letter_from_FDA_CDRH_to_Pyrexar_Med.pdf,"October 28, 2024",Center for Devices and Radiological Health (CDRH),Denied,"Section 513(e), Section 513(f)(1), Section 513(f)(3), Section 520(m), Section 513(a)(1)(B) of the FD&C Act; 21 CFR 860.130(e); 21 CFR 860.123(a)(7)",The petition was misfiled under section 513(e) instead of the correct section 513(f)(3); the petitioner failed to provide sufficient information for FDA to determine that special controls would provide reasonable assurance of safety and effectiveness; supporting evidence cited was not adequately detailed or properly included as source documents; the intended use was unclear and did not match the approved indication under the HDE.,
FDA-2024-P-2885-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"October 18, 2024",CDER (Center for Drug Evaluation and Research),Approved,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii)","The proposed change in strength from the listed drug product does not pose questions of safety or effectiveness. The proposed drug products have the same use, dose, dosage form, and route of administration as the listed drug. The change is consistent with the labeling of the listed drug, and if bioequivalence is demonstrated, the proposed products are expected to have the same therapeutic effect. Therefore, investigations are not necessary to demonstrate safety and effectiveness.",
FDA-2024-P-2909-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"October 15, 2024",CDER (Center for Drug Evaluation and Research),Approved,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii)","The FDA determined that the proposed change in strength (from 2 mg and 8 mg to 4 mg and 12 mg) does not pose questions of safety or effectiveness, aligns with the listed drug’s labeling, maintains the same use, dose, dosage form, and route of administration, and, if bioequivalence is met, can be expected to have the same therapeutic effect.",
FDA-2024-P-2932-0007_Response_Letter_from_FDA_CDER_to_Newcastle_Bioscie.pdf,"December 20, 2024",Center for Drug Evaluation and Research (CDER),Denied,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; Section 505B of the Act (Pediatric Research Equity Act - PREA); Section 505B(k) of the Act","The FDA denied the petition because the requested change in dosage form (from tablets to orally disintegrating tablets) triggered the requirement for pediatric studies under PREA. The agency determined that clinical trials are necessary for pediatric patients aged 2 to less than 7 years with HoFH, and a waiver request was denied. Additionally, the petitioner had not obtained orphan drug designation for the proposed product and therefore did not qualify for the PREA orphan exemption.",
FDA-2024-P-2933-0002_Acknowledgment_Letter_from_FDA_DMS_to_Chobani_LLC.pdf,"June 21, 2024",Dockets Management Staff (FDA/Office of Operations),Acknowledged,CFR 10.30,The petition was received and processed; acceptance for filing is procedural and does not reflect a decision on the petition's substantive merits,
FDA-2024-P-2952-0005_Interim_Response_Letter_from_FDA_CDER_to_Sarah_A__.pdf,"December 16, 2024",Center for Drug Evaluation and Research (CDER),Interim Response,21 CFR 10.30(e)(2),"The petition raises complex issues requiring extensive review and analysis by Agency officials; therefore, a final decision has not yet been reached.",
FDA-2024-P-2955-0006_Interim_Response_Letter_from_FDA_CDER_to_Dsquare_L.pdf,"December 10, 2024",CDER (Center for Drug Evaluation and Research),Interim response – decision not yet made,21 CFR 10.30(e)(2),The FDA has not reached a decision due to the need to address other Agency priorities and states that a response will be provided as soon as possible.,
FDA-2024-P-3090-0011_Response_Letter_from_FDA_CDER_to_Epic_Pharma__LLC.pdf,"December 11, 2024",Center for Drug Evaluation and Research (CDER),Denied,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; Section 505B of the Act (Pediatric Research Equity Act - PREA)","The petition was denied because the proposed change in dosage form (from tablets to oral suspension) triggered the need for pediatric studies under PREA. While a partial waiver was granted for patients from birth to less than 1 month old, the FDA denied a waiver for patients aged 1 month to less than 4 years. Therefore, clinical trials are required, making the product ineligible for ANDA approval under a suitability petition.",
FDA-2024-P-3188-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"November 6, 2024",CDER (Center for Drug Evaluation and Research),Approved,"Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii)","The proposed change in strength does not pose questions of safety or effectiveness; the proposed product has the same uses, dose, dosage form, and route of administration as the listed drug; the change is consistent with existing labeling; if shown to meet bioequivalence requirements, it is expected to have the same therapeutic effect as the reference drug; no significant labeling changes or new investigations are required.",
FDA-2024-P-3292-0013_Suitability_Petition_Approval_from_FDA_CVM_to_Feli.pdf,"October 8, 2024",Center for Veterinary Medicine (CVM),Approved,"Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 CFR 514.5","The proposed change in dosage form from tablet to oral solution does not require new investigations to demonstrate safety and effectiveness for the intended uses, and thus meets the criteria for approval under a suitability petition.",
FDA-2024-P-3293-0011_Final_Response_Letter_from_FDA_CDER_to_Newcastle_B.pdf,"December 26, 2024",CDER (Center for Drug Evaluation and Research),Approved,"505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act; 21 CFR 314.93; 21 CFR 314.93(e)(1); 505B of the Act; 505(j)(2)(A)(iv); 21 CFR 314.94(a)(3)(iii)","The proposed changes in strength and dosage form (from tablets to orally disintegrating tablets) do not pose questions of safety or effectiveness; uses, dose, and route of administration are the same as the listed drug; proposed changes align with dosing recommendations; bioequivalence, if demonstrated, would ensure same therapeutic effect; pediatric studies were deemed unnecessary for specific age groups due to impracticability.",
FDA-2024-P-3357-0004_Final_Response_Letter_from_FDA_CDRH_to_Randall_Hen.pdf,"January 10, 2025",CDRH (Center for Devices and Radiological Health),Denied,"21 CFR 10.30, 21 U.S.C. § 360f(a), Section 201(h)(1) of the FD&C Act, 21 CFR part 814, 21 CFR part 807 subpart E, 21 CFR 801.4, 21 CFR 809.3, 21 CFR 895.21, 42 CFR part 493","FDA found insufficient information to determine whether the paternity tests qualify as devices under the FD&C Act, and even if they were devices, there was not enough evidence to show they pose a substantial deception or risk of illness/injury. FDA also does not have authority to revoke AABB’s CLIA-related accreditation authority, which is under CMS jurisdiction. Requests for enforcement action and market bans were also outside the scope of the citizen petition process or unsupported.",
FDA-2024-P-3357-0004_Final_Response_Letter_from_FDA_CDRH_to_Randall_Hen.pdf,"January 10, 2025",Center for Devices and Radiological Health (CDRH),Denied,21 CFR 10.30(e); 21 CFR 10.30(k); Section 516(a) of the FD&C Act (21 U.S.C. § 360f(a)); Section 201(h)(1) of the FD&C Act (21 U.S.C. § 321(h)(1)); 21 CFR part 814; 21 CFR part 807 subpart E; 21 CFR 801.4; 21 CFR 895.21(a)(1); 21 CFR 895.21(a)(2); 42 CFR part 493; 21 CFR 809.3,Insufficient evidence that duo paternity tests are FDA‑regulated devices or pose substantial deception or unreasonable and substantial risk; FDA lacks authority to revoke AABB’s CLIA accreditation or transfer it to ASCLD; enforcement and market‑ban requests lie outside citizen‑petition scope.,
FDA-2024-P-3479-0003_Final_Response_Letter_from_FDA_CDER_to_Jingwei_Pha.pdf,"December 20, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j) of the FD&C Act (21 U.S.C. § 355(j)); Sections 505(j)(2)(A) and 505(j)(4) of the FD&C Act; Section 501(a)(2)(B) of the FD&C Act; 21 CFR 314.3(b); 21 CFR 314.94; 21 CFR 314.127; 21 CFR parts 210 and 211,"FDA found that existing case‑by‑case ANDA reviews, USP standards, and cGMP regulations already ensure sitagliptin quality and patient safety; biocatalytic manufacture does not pose greater risk, and the petition lacked evidence to justify mandatory certificates, detailed catalyst data, or additional impurity testing for all applicants.",
FDA-2024-P-3484-0002_Acknowledgement_Letter_from_FDA_CDRH_to_Foundation.pdf,"August 5, 2024",Center for Devices and Radiological Health (CDRH),Other (Acknowledgement of receipt only),21 CFR 10.30,FDA acknowledged receipt of the petition requesting reclassification of certain next-generation sequencing oncology panel devices from class III to class II. The letter clarifies that acceptance for filing is procedural and does not reflect a substantive decision.,
FDA-2024-P-3563-0005_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"December 18, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(b)(2) of the FD&C Act (21 U.S.C. § 355(b)(2)); Section 505(c) of the FD&C Act; 21 CFR 314.3; 21 CFR 314.54(a); FDA guidance documents cited include 'Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerations' and 'Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment',FDA found insufficient evidence that low-volume nasal spray drug products like Valtoco are significantly swallowed or subject to meaningful food effects; the literature and adverse event data did not demonstrate clinically relevant enteral absorption or efficacy issues due to food; FAERS data review revealed no reliable signal for lack of efficacy attributable to food effects.,
FDA-2024-P-3567-0007_Response_Letter_from_FDA_CDER_to_Lachman_Consultin.pdf,"January 28, 2025",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(i); 21 CFR 314.93(e)(1)(iv); 21 CFR 10.20; 21 CFR 10.33,"FDA determined that the proposed changes in strength (25 mg, 50 mg, 100 mg) raise safety and effectiveness concerns not supported by the reference listed drug (RLD) labeling; such changes would require significant labeling modifications and additional investigations to ensure safe and effective use, making them inappropriate for approval under the ANDA petition process.",
FDA-2024-P-3571-0009_Final_Response_Letter_from_FDA_CDER_to_Premier_Con.pdf,"December 26, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; Section 505B of the FD&C Act (PREA); 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii),"FDA determined that the proposed change from capsule to oral liquid dosage form does not raise safety or effectiveness concerns, is consistent with the listed drug’s labeling, and does not require significant labeling changes or additional investigations; pediatric study requirements under PREA were waived due to lack of meaningful therapeutic benefit and limited pediatric use.",
FDA-2024-P-3573-0005_Response_Letter_from_FDA_CDER_to_Premier_Research_.pdf,"January 15, 2025",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; Section 505B of the FD&C Act (PREA); 21 CFR 314.93; 21 CFR 314.94(a)(3)(iii),"FDA determined that the proposed change from tablet to oral liquid dosage form does not raise concerns regarding safety or effectiveness, aligns with the labeled dosing recommendations, and does not require significant labeling changes; pediatric studies were waived under PREA due to lack of meaningful benefit and expected limited pediatric use.",
FDA-2024-P-3699-0004_Response_Letter_from_FDA_CDER_to_Zydus_Pharmaceuti.pdf,"November 20, 2024",Center for Drug Evaluation and Research (CDER),Denied,Not Mentioned,"FDA determined that IC-GREEN (Indocyanine Green), 25 mg/vial, was not withdrawn from sale for reasons of safety or effectiveness and will remain listed in the Orange Book’s Discontinued Drug Product List.",
FDA-2024-P-3761-0003_Final_Response_Letter_from_FDA_CDRH_to_Spark_Biome.pdf,"December 15, 2024",Center for Devices and Radiological Health (CDRH),Denied,21 CFR 10.30(k); 21 CFR 10.30(b)(3); 21 CFR 10.3(a),"FDA denied the petition because requests for enforcement actions, investigations, or related regulatory activities fall outside the scope of citizen petition procedures; such actions are within the agency’s discretion and not subject to petitions from external parties.",
FDA-2024-P-3799-0002_Acknowledgement_Letter_from_FDA_DMS_to_Raaha_LLC.pdf,"August 9, 2024","Dockets Management Staff (DMS), Office of Operations (OO)",Other (Acknowledgement of receipt only),21 CFR 10.30,"FDA acknowledged receipt of the petition dated August 7, 2024, and clarified that acceptance for filing is a procedural step that does not reflect any decision on the substantive merits of the petition.",
FDA-2024-P-3820-0011_Interim_Response_Letter_from_FDA_HFP_to_Agent_for_.pdf,"February 6, 2025","Human Foods Program (HFP), Office of Nutrition and Food Labeling",Other (Interim Response – No decision yet),21 CFR 10.30(e)(2),FDA stated it has not yet reached a decision on the petition to amend 21 CFR § 101.9(c)(6)(i) to include Isomaltodextrin (Fibryxa®) due to other agency priorities and limited resources; a final decision will be provided upon completion of the review.,
FDA-2024-P-3821-0004_Final_Response_Letter_from_FDA_CVM_to_Aurora_Pharm.pdf,"October 28, 2024",Center for Veterinary Medicine (CVM),Approved,Section 512(n)(3) and Section 512(n)(3)(C) of the FD&C Act; 21 CFR 514.5,"FDA approved the suitability petition for afoxolaner oral solution as a generic version of NexGard® chewable tablets, finding that the change in dosage form does not require new investigations to demonstrate safety and effectiveness for the intended uses.",
FDA-2024-P-3822-0003_Interim_Response_Letter_from_FDA_CDER_to_Universit.pdf,"February 4, 2025",Center for Drug Evaluation and Research (CDER),Other (Interim Response – No decision yet),21 CFR 10.30(e)(2),FDA has not yet resolved the issues raised in the petition concerning the US Pharmacopeia’s modification of biological drug monographs due to their complexity; a final response will be issued once a decision is reached.,
FDA-2024-P-3881-0007_Response_Letter_from_FDA_CDER_to_Zydus_Pharmaceuti.pdf,"December 16, 2024",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii),"FDA determined that the proposed change in strength (to 34 mg) for Pimavanserin Tablets does not pose questions of safety or effectiveness, is consistent with labeling, and does not require significant labeling changes or additional investigations; bioequivalence will be assessed during ANDA review.",
FDA-2024-P-3905-0008_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"February 12, 2025",Center for Drug Evaluation and Research (CDER),Approved,Section 505(j)(2)(C) of the FD&C Act; Section 505(j)(2)(A) and (B); Section 505(j)(2)(A)(iv); 21 CFR 314.93; 21 CFR 314.93(e)(1); 21 CFR 314.94(a)(3)(iii),"FDA determined that the proposed change in dosage form from cream to vaginal inserts does not pose safety or effectiveness concerns, is consistent with the labeled dosing of the reference product, and does not require significant labeling changes or new investigations; bioequivalence will be evaluated during ANDA review.",
FDA-2024-P-3997-0006_Interim_Response_Letter_from_FDA_CDER_to_Aylstock_.pdf,"February 13, 2025",Center for Drug Evaluation and Research (CDER),Other (Interim Response – No decision yet),21 CFR 10.30(e)(2),"FDA has not yet resolved the petition requesting market recall of benzoyl peroxide products due to alleged benzene contamination; the issues are complex and require extensive review. Additionally, FDA noted that the petitioner has not yet submitted the testing data referenced in the petition despite multiple requests.",
FDA-2024-P-4015-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,"November 7, 2024",Center for Veterinary Medicine (CVM),Denied,5 U.S.C. § 552(a)(2)(D); 29 U.S.C. § 794d(a); 21 CFR 10.30(b)(3),"FDA denied the petition requesting public posting of certain records, stating that such posting is governed by the Freedom of Information Act (FOIA) and Section 508 accessibility requirements; records will be posted when required under FOIA and once made compliant with accessibility standards.",
FDA-2024-P-4126-0006_Letter_from_FDA_CVM_to_Aurora_Pharmaceutical__Inc_.pdf,"October 10, 2024",Center for Veterinary Medicine (CVM),Approved,Section 512(n)(3) and Section 512(n)(3)(C) of the FD&C Act; 21 CFR 514.5,"FDA approved the suitability petition for a generic meloxicam oral solution (3 mg/mL) differing in dosage form and strength from the reference listed drug (Metacam® 1.5 mg/mL), concluding that no new investigations are required to demonstrate safety and effectiveness for the intended uses.",
FDA-2024-P-4134-0009_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"February 18, 2025",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(iv); 21 CFR 10.20; 21 CFR 10.33,FDA denied the petition because the proposed new strength of 37.5 mg for Diclofenac Potassium Tablets raises safety and effectiveness concerns that would necessitate significant labeling changes. The 37.5 mg strength is not supported by the reference listed drug’s labeling and could increase the risk of medication errors and confusion among patients and prescribers.,
FDA-2024-P-4135-0004_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"November 13, 2024",Center for Drug Evaluation and Research (CDER),Denied,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93; 21 CFR 314.93(e)(1)(vi); 21 CFR 10.20; 21 CFR 10.33,"FDA denied the petition because the proposed strength of Vasopressin in 0.9% Sodium Chloride Injection (50 units/50 mL) is already approved under NDAs 217766 and 204485; under 21 CFR 314.93(e)(1)(vi), a petition must be denied if a drug product with the proposed change is already approved in an NDA.",